Q3
QUOTATION
“————
Recent Highlights & Developments
BRIUMVI® (ublituximab-xiiy) Commercialization
BRIUMVI U.S. net product revenue of $152.9 million for the third quarter of 2025, representing 84% growth over the same period in 2024 and 10% growth over Q2 2025
Expansion of commercialization outside of the U.S. with our partner, Neuraxpharm, with BRIUMVI now approved in the European Union, United Kingdom, Switzerland, Australia, Kuwait and the United Arab Emirates
_——————-“
投資の参考になりましたか?

